Mathew Blackman

Stock Analyst at Stifel

(1.42)
# 1899
Out of 5,441 analysts
69
Total ratings
Success rate
Average return
17 Stocks
Name Action PT Current % Upside Ratings Updated
INGN Inogen
Maintains: Hold
10 7
7.03 -0.43% 12 May 8, 2025
TNDM Tandem Diabetes Care
Maintains: Buy
60 31
10.11 206.63% 6 May 1, 2025
PEN Penumbra
Maintains: Strong Buy
301 318
239.88 32.57% 2 Apr 24, 2025
CLPT ClearPoint Neuro
Maintains: Strong Buy
19 25
10.6 135.85% 3 Apr 1, 2025
BBNX Beta Bionics
Initiates Coverage On: Buy
25
14.29 74.95% 1 Feb 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
245 293
304.75 -3.86% 5 Feb 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
92 94
59.45 58.12% 5 Feb 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
18 24
12.95 85.33% 5 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
6 3
1.25 140% 1 Oct 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Hold
50
79.97 -37.48% 1 Sep 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
90 100
77.88 28.4% 11 Aug 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
19 16
15.31 4.51% 5 Aug 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
18 11
9.35 17.65% 4 May 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
10
10 0% 3 Jan 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
18 16
9.54 67.71% 2 Mar 14, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
64
39.75 61.01% 1 Oct 20, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
30
n/a n/a 2 Aug 26, 2020